Trial Profile

A Proof of Concept Study to Evaluate the Coadministration of TT223 Given Daily and LY2428757 Given Once-Weekly for Four Weeks in Patients With Type 2 Diabetes Mellitus

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LY 2428757 (Primary) ; TT 223 (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use
Sponsors Eli Lilly and Company

Most Recent Events

12 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
17 Sep 2010 Results have been reported in a Transition Therapeutics media release.
17 Sep 2010 Primary endpoint 'Proportion of glycosylated haemoglobin' has not been met according to a Transition Therapeutics media release. TT 223 is no-longer being developed by Transition Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com